[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First People's Hospital of Shenyang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053876","environmental-perturbation-balance-training-improves-functional-outcomes-in-patients-with-subacute-stroke-100053876",false,"NCT07697794","Environmental-perturbation Balance Training Improves Functional Outcomes in Patients With Subacute Stroke","Environmental-Perturbation Balance Training Improves Functional Outcomes in Patients With Subacute Stroke: A Prospective Randomized Controlled Trial","E-PBT","Inclusion Criteria:\n\nDiagnosed with stroke according to the International Symposium on Cerebral Vascular Disease criteria, with definite confirmation by imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI).\n\nFirst-ever or recurrent cerebral hemorrhage or cerebral infarction. According to the Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association\u002FAmerican Stroke Association\\[11\\] and the Chinese Guidelines for Early Rehabilitation of Stroke\\[12\\], rehabilitation can be initiated once the patient's condition is stable (vital signs are stable and no further progression of symptoms and signs).\n\nTotal NIHSS score between 5 and 20 (inclusive) prior to randomization, with a lower limb motor score ≥2.\n\nPresence of balance dysfunction, with a miniBESTest total score ≤12. Good compliance with rehabilitation therapy and no contraindications to active training.\n\nAge between 18 and 85 years. The subject or their legal representative is able and willing to provide written informed consent.\n\nExclusion Criteria:\n\nHistory of prior cerebral hemorrhage or cerebral infarction with residual significant limb dysfunction.\n\nSevere cognitive impairment or sensory aphasia that precludes communication and cooperation with treatment.\n\nConcomitant severe cardiopulmonary, hepatic, or renal insufficiency, or other serious medical diseases.\n\nPresence of neurological or musculoskeletal disorders affecting balance function prior to stroke onset.\n\nUncontrolled severe hypertension or diabetes mellitus. Active bleeding or deep vein thrombosis. Current participation in another clinical trial or rehabilitation program that may affect the results of this study.\n\nAny other condition that may interfere with the outcomes of this study. History of limb amputation affecting bilateral coordination or independent walking ability.\n\nPregnancy.","ALL","18 Years","85 Years",{"count":21,"type":22},148,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study innovatively proposes an \"environment-perturbation balance training (E-PBT)\" intervention, which delivers stable, graded environmental perturbations to keep the challenges within the manageable range. This approach can significantly reduce fear, align with the psychological characteristics of subacute stroke patients, and improve training engagement and safety, thereby filling the current research gap that has insufficiently addressed subacute patients and those with moderate-to-low functional levels. By altering the size and angle of the support surface, this training heightens patients' alertness and psychological adaptability, prompting them to actively integrate sensory information and adjust motor strategies. In turn, this can more effectively reshape internal model of balance control and facilitate genuine neuroadaptive learning in the brain. Moreover, this training more closely mimics real-life fall scenarios, with the aim of directly cultivating the proactive postural control and strategic decision-making abilities required in daily living.\n\nThis study aims to systematically evaluate the efficacy of this E-PBT intervention on functional recovery in patients during the subacute stage of stroke through a prospective randomized controlled trial, and to explore its potential effects on balance ability, activities of daily living, and overall functional outcomes, thereby providing a more effective and clinically translatable new strategy for post-stroke rehabilitation.",[28],"Stroke",[28,30,31,32,33,34],"Subacute stage","Functional prognosis","Environment-perturbation balance training","Randomized controlled trial","Modified Rankin Scale","NOT_YET_RECRUITING","2026-07-09",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-07-20",{"date":43,"type":22},"2027-12-01",{"name":45,"class":46},"First People's Hospital of Shenyang","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100555084","daphnetin-capsule-in-the-treatment-of-vascular-cognitive-impairment-without-dementia-100555084","NCT06507488","Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia","Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia - A Randomized, Double-blind, Placebo-controlled Study","DISCO","Inclusion Criteria:\n\n1. Be 50-80 years of age (both ends included)\n2. Have a complaint of cognitive impairment involving memory and\u002For other cognitive domains that has persisted for at least 3 months\n3. Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria）, a Montreal Cognitive Assessment (MoCA scale) score \\\u003C26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1\n4. Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \\\u003C26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1\n5. Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition\n2. Acute stroke event within 6 months\n3. Previously diagnosed hereditary or inflammatory small vessel disease\n4. Presence of congenital mental retardation and severe neurological or psychiatric disorders\n5. Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation\n6. Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium)\n7. Combined severe cardiac, pulmonary, and renal insufficiency (creatinine \\> 2.0 mg\u002Fdl or 177 μ mol\u002FL), and severe hepatic impairment (aminotransferases more than 3 times normal)\n8. Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics\n9. Malignant tumors that have been clearly diagnosed, vital organ failure\n10. Those with bleeding tendency after surgery\n11. Pregnant and lactating women are prohibited\n12. Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and\u002For Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited\n13. Previous allergy or intolerance to the ingredients of Reserpine\n14. The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study\n15. Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies.","50 Years","80 Years",{"count":59,"type":22},206,[25],"The purpose of this clinical trial is to understand and evaluate the clinical efficacy and safety of Daphnetin Capsule in patients with vascular cognitive impairment. Changes in the Vascular Dementia Assessment Scale-cog(VADAS-cog) at 6 months were evaluated. Although Daphnetin has a dual neurovascular protective effect, however, there is still a lack of relevant high-quality studies on its role in patients with vascular cognitive impairment, especially in patients with vascular cognitive impairment in non-dementia (VCI-ND), whether it has a role in improving cognitive status needs to be urgently explored in high-quality clinical studies. Researchers are comparing Daphnetin to placebo (a drug-free analog) to see if Daphnetin is effective in treating vascular cognitive impairment. Participants will take either Daphnetin or placebo daily for six months, with follow-up visits every three months and completion of a case report form.",[63],"Cerebrovascular Disorders",[65,66,67,68],"Vascular Cognitive Impairment No Dementia","Daphnetin","Effectiveness","safety","RECRUITING","2025-08-21",{"date":72,"type":39},"2025-08-28",{"date":74,"type":39},"2025-07-07",{"date":76,"type":22},"2026-04-30",{"name":45,"class":46},""]